vs
CoreCivic, Inc.（CXW）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是CoreCivic, Inc.的1.0倍（$622.0M vs $604.0M），Royalty Pharma plc净利率更高（34.4% vs 4.4%，领先30.0%），CoreCivic, Inc.同比增速更快（26.0% vs 4.8%），过去两年CoreCivic, Inc.的营收复合增速更高（9.8% vs 4.6%）
CoreCivic, Inc.是美国私营监狱运营企业，为美国规模最大的营利性监狱、看守所及拘留设施承包商之一。该公司在美国运营70余座州级及联邦惩教、拘留场所，曾因相关场所被指存在民权侵犯、强迫劳动问题，成为撤资运动针对对象，还遭到FBI调查及多起诉讼。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
CXW vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.0倍
$604.0M
营收增速更快
CXW
高出21.2%
4.8%
净利率更高
RPRX
高出30.0%
4.4%
两年增速更快
CXW
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $604.0M | $622.0M |
| 净利润 | $26.5M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 6.0% | 62.4% |
| 净利率 | 4.4% | 34.4% |
| 营收同比 | 26.0% | 4.8% |
| 净利润同比 | 37.7% | 2.9% |
| 每股收益（稀释后） | $0.26 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CXWRPRX
| Q4 25 | $604.0M | $622.0M | ||
| Q3 25 | $580.4M | $609.3M | ||
| Q2 25 | $538.2M | $578.7M | ||
| Q1 25 | $488.6M | $568.2M | ||
| Q4 24 | $479.3M | $593.6M | ||
| Q3 24 | $491.6M | $564.7M | ||
| Q2 24 | $490.1M | $537.3M | ||
| Q1 24 | $500.7M | $568.0M |
净利润CXWRPRX
| Q4 25 | $26.5M | $214.2M | ||
| Q3 25 | $26.3M | $288.2M | ||
| Q2 25 | $38.5M | $30.2M | ||
| Q1 25 | $25.1M | $238.3M | ||
| Q4 24 | $19.3M | $208.2M | ||
| Q3 24 | $21.1M | $544.0M | ||
| Q2 24 | $19.0M | $102.0M | ||
| Q1 24 | $9.5M | $4.8M |
营业利润率CXWRPRX
| Q4 25 | 6.0% | 62.4% | ||
| Q3 25 | 6.3% | 70.1% | ||
| Q2 25 | 9.7% | 36.3% | ||
| Q1 25 | 6.6% | 94.0% | ||
| Q4 24 | 5.2% | 60.9% | ||
| Q3 24 | 6.1% | — | ||
| Q2 24 | 5.6% | 50.2% | ||
| Q1 24 | 1.8% | -13.0% |
净利率CXWRPRX
| Q4 25 | 4.4% | 34.4% | ||
| Q3 25 | 4.5% | 47.3% | ||
| Q2 25 | 7.2% | 5.2% | ||
| Q1 25 | 5.1% | 41.9% | ||
| Q4 24 | 4.0% | 35.1% | ||
| Q3 24 | 4.3% | 96.3% | ||
| Q2 24 | 3.9% | 19.0% | ||
| Q1 24 | 1.9% | 0.8% |
每股收益（稀释后）CXWRPRX
| Q4 25 | $0.26 | $0.49 | ||
| Q3 25 | $0.24 | $0.67 | ||
| Q2 25 | $0.35 | $0.07 | ||
| Q1 25 | $0.23 | $0.55 | ||
| Q4 24 | $0.18 | $0.46 | ||
| Q3 24 | $0.19 | $1.21 | ||
| Q2 24 | $0.17 | $0.23 | ||
| Q1 24 | $0.08 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.9M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $1.4B | $9.7B |
| 总资产 | $3.3B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资CXWRPRX
| Q4 25 | $97.9M | $618.7M | ||
| Q3 25 | $56.6M | $938.9M | ||
| Q2 25 | $130.5M | $631.9M | ||
| Q1 25 | $74.5M | $1.1B | ||
| Q4 24 | $107.5M | $929.0M | ||
| Q3 24 | $107.8M | $950.1M | ||
| Q2 24 | $60.2M | $1.8B | ||
| Q1 24 | $111.4M | $843.0M |
总债务CXWRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益CXWRPRX
| Q4 25 | $1.4B | $9.7B | ||
| Q3 25 | $1.5B | $9.6B | ||
| Q2 25 | $1.5B | $9.5B | ||
| Q1 25 | $1.5B | $9.8B | ||
| Q4 24 | $1.5B | $10.3B | ||
| Q3 24 | $1.5B | $10.3B | ||
| Q2 24 | $1.4B | $9.8B | ||
| Q1 24 | $1.4B | $9.9B |
总资产CXWRPRX
| Q4 25 | $3.3B | $19.6B | ||
| Q3 25 | $3.1B | $19.3B | ||
| Q2 25 | $3.1B | $18.3B | ||
| Q1 25 | $3.0B | $17.6B | ||
| Q4 24 | $2.9B | $18.2B | ||
| Q3 24 | $2.9B | $18.0B | ||
| Q2 24 | $2.9B | $17.7B | ||
| Q1 24 | $3.0B | $16.1B |
负债/权益比CXWRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-376.0K | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-45.1M | — |
| 自由现金流率自由现金流/营收 | -7.5% | — |
| 资本支出强度资本支出/营收 | 7.4% | — |
| 现金转化率经营现金流/净利润 | -0.01× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $52.8M | — |
8季度趋势，按日历期对齐
经营现金流CXWRPRX
| Q4 25 | $-376.0K | $827.1M | ||
| Q3 25 | $53.8M | $702.6M | ||
| Q2 25 | $96.7M | $364.0M | ||
| Q1 25 | $44.5M | $596.1M | ||
| Q4 24 | $39.3M | $742.5M | ||
| Q3 24 | $91.5M | $703.6M | ||
| Q2 24 | $68.1M | $658.2M | ||
| Q1 24 | $70.4M | $664.6M |
自由现金流CXWRPRX
| Q4 25 | $-45.1M | — | ||
| Q3 25 | $16.1M | — | ||
| Q2 25 | $61.9M | — | ||
| Q1 25 | $20.0M | — | ||
| Q4 24 | $16.0M | — | ||
| Q3 24 | $73.7M | — | ||
| Q2 24 | $49.3M | — | ||
| Q1 24 | $59.7M | — |
自由现金流率CXWRPRX
| Q4 25 | -7.5% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 11.5% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 15.0% | — | ||
| Q2 24 | 10.1% | — | ||
| Q1 24 | 11.9% | — |
资本支出强度CXWRPRX
| Q4 25 | 7.4% | — | ||
| Q3 25 | 6.5% | — | ||
| Q2 25 | 6.5% | — | ||
| Q1 25 | 5.0% | — | ||
| Q4 24 | 4.9% | — | ||
| Q3 24 | 3.6% | — | ||
| Q2 24 | 3.8% | — | ||
| Q1 24 | 2.1% | — |
现金转化率CXWRPRX
| Q4 25 | -0.01× | 3.86× | ||
| Q3 25 | 2.04× | 2.44× | ||
| Q2 25 | 2.51× | 12.06× | ||
| Q1 25 | 1.77× | 2.50× | ||
| Q4 24 | 2.04× | 3.57× | ||
| Q3 24 | 4.34× | 1.29× | ||
| Q2 24 | 3.59× | 6.45× | ||
| Q1 24 | 7.37× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CXW
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
